{"id":"placebo-to-benralizumab","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Injection site reaction"}]},"_chembl":{"chemblId":"CHEMBL1742991","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Benralizumab works by binding to the interleukin-5 receptor alpha subunit on the surface of eosinophils, which are a type of white blood cell involved in inflammation. This binding leads to the depletion of eosinophils, which are thought to contribute to the inflammation and damage seen in conditions such as asthma and chronic obstructive pulmonary disease (COPD).","oneSentence":"Benralizumab is a monoclonal antibody that targets the interleukin-5 receptor alpha subunit, leading to the depletion of eosinophils.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:34.011Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe asthma"},{"name":"Chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT06750289","phase":"PHASE3","title":"Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-28","conditions":"Eosinophilic Asthma","enrollment":400},{"nctId":"NCT03953300","phase":"PHASE4","title":"Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-10-08","conditions":"Asthma","enrollment":75},{"nctId":"NCT05692180","phase":"PHASE3","title":"A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-04-05","conditions":"Asthma","enrollment":200},{"nctId":"NCT04191304","phase":"PHASE3","title":"A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-07-20","conditions":"Hypereosinophilic Syndrome","enrollment":134},{"nctId":"NCT04157348","phase":"PHASE3","title":"Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-10-29","conditions":"Eosinophilic Granulomatous Vasculitis","enrollment":140},{"nctId":"NCT04718389","phase":"PHASE3","title":"A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-01-26","conditions":"Asthma","enrollment":1719},{"nctId":"NCT03563066","phase":"PHASE2","title":"Effect of Benralizumab in Atopic Dermatitis","status":"COMPLETED","sponsor":"McMaster University","startDate":"2018-09-04","conditions":"Dermatitis, Atopic, Dermatitis, Eczema","enrollment":20},{"nctId":"NCT04053634","phase":"PHASE3","title":"Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-08-26","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":689},{"nctId":"NCT05006573","phase":"PHASE3","title":"Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-07-21","conditions":"Non-cystic Fibrosis Bronchiectasis","enrollment":100},{"nctId":"NCT05251909","phase":"PHASE3","title":"Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2022-01-18","conditions":"Eosinophilic Gastritis, Eosinophilic Gastroenteritis","enrollment":12},{"nctId":"NCT06734884","phase":"PHASE2","title":"Interest of a Targeted Therapy for the Treatment of a Severe Form of Hypersensitivity to Drug (DRESS Syndrome)","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Lille","startDate":"2025-01-06","conditions":"DRESS Syndrome","enrollment":96},{"nctId":"NCT04612790","phase":"PHASE3","title":"A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-03-31","conditions":"Bullous Pemphigoid","enrollment":67},{"nctId":"NCT04185012","phase":"PHASE3","title":"NAsal Polyps: Inflammatory & Molecular Phenotyping of Responders to Benralizumab","status":"COMPLETED","sponsor":"Humanitas Clinical and Research Center","startDate":"2020-02-24","conditions":"Nasal Polyps","enrollment":14},{"nctId":"NCT03186209","phase":"PHASE3","title":"Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-09-07","conditions":"Asthma","enrollment":695},{"nctId":"NCT04612725","phase":"PHASE2","title":"A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2020-10-27","conditions":"Chronic Spontaneous Urticaria","enrollment":159},{"nctId":"NCT04098718","phase":"PHASE2","title":"Acute Exacerbations Treated With BenRAlizumab (The ABRA Study)","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2021-03-29","conditions":"Asthma, COPD","enrollment":158},{"nctId":"NCT05528913","phase":"PHASE2","title":"Benralizumab in Chronic Prurigo - Investigating Clinical Efficacy (BICPIC)","status":"WITHDRAWN","sponsor":"Charite University, Berlin, Germany","startDate":"2023-10","conditions":"Chronic Prurigo","enrollment":""},{"nctId":"NCT04543409","phase":"PHASE3","title":"A Study of Benralizumab in Patients With Eosinophilic Esophagitis","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2020-09-22","conditions":"Eosinophilic Esophagitis","enrollment":211},{"nctId":"NCT04605094","phase":"PHASE2","title":"Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2020-11-12","conditions":"Atopic Dermatitis","enrollment":194},{"nctId":"NCT03470311","phase":"PHASE3","title":"Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies","status":"COMPLETED","sponsor":"McMaster University","startDate":"2018-04-26","conditions":"Severe Prednisone Dependent Eosinophilic Asthma","enrollment":20},{"nctId":"NCT02130882","phase":"PHASE2, PHASE3","title":"Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome","status":"UNKNOWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-05-19","conditions":"Respiratory System Agents, Anti-Asthmatic Agents, Hematologic Diseases","enrollment":20},{"nctId":"NCT03473977","phase":"PHASE2, PHASE3","title":"Benralizumab for Eosinophilic Gastritis (BEGS)","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2018-04-23","conditions":"Eosinophilic Gastritis or Gastroenteritis","enrollment":26},{"nctId":"NCT03170271","phase":"PHASE3","title":"A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-07-07","conditions":"Asthma","enrollment":660},{"nctId":"NCT03401229","phase":"PHASE3","title":"Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-01-15","conditions":"Nasal Polyposis","enrollment":413},{"nctId":"NCT02821416","phase":"PHASE3","title":"Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-10-11","conditions":"Asthma","enrollment":46},{"nctId":"NCT00768079","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563).","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2009-02-02","conditions":"Asthma","enrollment":110},{"nctId":"NCT00783289","phase":"PHASE2","title":"A Phase 2a Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Adults With Asthma","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2008-11-14","conditions":"Asthma","enrollment":35},{"nctId":"NCT02869438","phase":"PHASE3","title":"A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-11-09","conditions":"Asthma","enrollment":233},{"nctId":"NCT03183024","phase":"PHASE4","title":"Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody","status":"COMPLETED","sponsor":"Jonathan A. Bernstein, MD","startDate":"2017-09-12","conditions":"Chronic Idiopathic Urticaria","enrollment":12},{"nctId":"NCT02155660","phase":"PHASE3","title":"Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-06-25","conditions":"Moderate to Very Severe Chronic Obstructive Pulmonary Disease","enrollment":2255},{"nctId":"NCT02138916","phase":"PHASE3","title":"Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-06-13","conditions":"Moderate to Very Severe Chronic Obstructive Pulmonary Disease","enrollment":1656},{"nctId":"NCT02814643","phase":"PHASE3","title":"Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-07-01","conditions":"Asthma","enrollment":103},{"nctId":"NCT02075255","phase":"PHASE3","title":"Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-04-28","conditions":"Asthma","enrollment":220},{"nctId":"NCT02322775","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-02-02","conditions":"Asthma","enrollment":211},{"nctId":"NCT01928771","phase":"PHASE3","title":"Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-09-19","conditions":"Asthma","enrollment":2681},{"nctId":"NCT01914757","phase":"PHASE3","title":"Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-08","conditions":"Asthma","enrollment":2508},{"nctId":"NCT01238861","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2010-12","conditions":"Asthma","enrollment":964},{"nctId":"NCT01227278","phase":"PHASE2","title":"A Study to Evaluate the Effectiveness of MEDI-563 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2010-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":421},{"nctId":"NCT01947946","phase":"PHASE3","title":"Efficacy and Safety Study of Benralizumab Added to Medium-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2013-11","conditions":"Asthma","enrollment":13},{"nctId":"NCT00659659","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability and Effects of MEDI-563 in Adults With Asthma","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2008-01","conditions":"Asthma","enrollment":27}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to Benralizumab","genericName":"Placebo to Benralizumab","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Biologic","firstApprovalDate":"","aiSummary":"Benralizumab is a monoclonal antibody that targets the interleukin-5 receptor alpha subunit, leading to the depletion of eosinophils. Used for Severe asthma, Chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}